Results 161 to 170 of about 20,698 (251)

Incretin‐Based Therapies as Cardiometabolic Interventions: Outcome Hierarchy, Receptor‐Network Pharmacology and Phenotype‐Based Clinical Positioning

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Incretin‐based pharmacotherapy was initially developed to improve glucose‐dependent insulin secretion and glycaemic control in type 2 diabetes, but its clinical interpretation has expanded substantially with cardiovascular outcome trials, kidney outcome data, obesity studies and next‐generation polyagonist development.
Ferenc Sztanek, Hajnalka Lőrincz, Mariann Harangi, Attila Csaba Nagy   +3 more
wiley   +1 more source

Retrospective Study of Real-World Treatment Patterns of Subcutaneous Semaglutide Use Among Patients with Metabolic Dysfunction-Associated Steatohepatitis in the United States

ClinicoEconomics and Outcomes Research
Yestle Kim,1 Ni Zeng,2 Jessamine P Winer-Jones,2 Machaon Bonafede,2 Francis Lobo,1 John O’Donnell,1 Taylor Ryan2 1Health Economics and Outcomes Research Madrigal Pharmaceuticals, Inc, West Conshohocken, PA, USA; 2Real World Evidence, Veradigm, Chicago ...
Kim Y, Zeng N, Winer-Jones JP, Bonafede M, Lobo F, O'Donnell J, Ryan T   +6 more
doaj  

Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST‐T1D Extension Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate changes in glycaemic control following semaglutide discontinuation in adults with Type 1 diabetes and obesity who completed the ADJUST‐T1D randomised controlled trial. Materials and Methods Continuous glucose monitoring (CGM) data were collected during a 12‐week extension phase after the ADJUST‐T1D trial.
Eslam Montaser, Kanchan Bhasin, Davida Kruger, Halis Kaan Akturk, Andrew Ahmann, Janet K. Snell‐Bergeon, Viral N. Shah   +6 more
wiley   +1 more source

Association of Tirzepatide versus Semaglutide with Risk of Asthma Exacerbation in Patients with Asthma and Type 2 Diabetes: A US Multicenter Retrospective Cohort Study. [PDF]

J Asthma Allergy
Hung CT, An CY, Suk CW, Lee TW, Hung SH.
europepmc   +1 more source

IDE-mediated GLP-1 degradation as the basis for designing long-acting and CNS-stable GLP-1 receptor agonists. [PDF]

Sci Adv
Zhang L, Liu X, Si C, Hou X, Hu X, Chen Y, Hu J, Turck CW, Shan B, Zhang Y.   +9 more
europepmc   +1 more source

Reasons for and Outcomes of Medicare Part D Appeals for Denied GLP‐1 Receptor Agonist Claims

Diabetes, Obesity and Metabolism, EarlyView.
Matthew J. Klebanoff, John C. Lin, Judith A. Long, Eric Bressman, Jalpa A. Doshi   +4 more
wiley   +1 more source

A Biweekly GLP‐1R Agonist Designed With Drug‐Free Intervals for Enhanced Efficacy, Receptor Homeostasis and Gastrointestinal Tolerability

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To develop a next‐generation, longer‐acting, more‐clinical‐benefits agonist to achieve sustained efficacy with improved tolerability. Methods CT130 was designed from semaglutide. Binding affinity was validated via molecular dynamics and cellular assays.
Wei Ding, Qing Liu, Qiong Luo, Xiaojun Yao, Xingxing Fan   +4 more
wiley   +1 more source

Semaglutide and pioglitazone restore airway mucosal homeostasis by resolving <i>Pseudomonas aeruginosa</i> pyocyanin-induced mucus hypersecretion, ciliostasis, and type 2 airway inflammation. [PDF]

Front Immunol
Wu C, Kulkarni NA, Lew SQ, Choi W, Sivaguru M, Kosmider B, Nanjappa SG, Lau GW.   +7 more
europepmc   +1 more source

Late-life semaglutide treatment slows ageing and extends lifespan in female mice. [PDF]

Nature
Feng Y, Barthez M, Wang Y, Chen Y, Qiu H, Wang CL, Heydari K, Delcroix M, Rasmussen LJ, Bohr VA, Chen D.   +10 more
europepmc   +1 more source

Preferences for Obesity Medications Among People With Overweight or Obesity in the United States: A Discrete‐Choice Experiment (OPTIC)

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the relative importance of attributes driving obesity medication (OM) choice and preferences among individuals with overweight or obesity. Materials and Methods US adults with obesity or overweight and ≥ 1 obesity‐related complication completed an online survey including a discrete‐choice experiment (DCE) in October–November ...
Jaime P. Almandoz, Beverly G. Tchang, Kelley Myers, Andrea Traina, Jigish Bhavsar, Victoria Divino, Cannon Kent, Sara Tadesse Bell   +7 more
wiley   +1 more source